



A mathematical model of methotrexate's effect on adalimumab immunogenicity in axial spondyloarthritis

Peter Rashkov¹, Sara Sottile², Denis Mulleman^{3,4}

¹Institute of Mathematics and Informatics,
Bulgarian Academy of Sciences, Bulgaria
p.rashkov@math.bas.bg

²Department of Medical and Surgical Sciences,
Alma Mater University of Bologna, Bologna, Italy
sara.sottile4@unibo.it

³Université de Tours, Tours, France

⁴Department of Rheumatology, CHRU de Tours, France
denis.mulleman@univ-tours.fr

Spondyloarthritis (SpA) is a chronic inflammatory disease impacting the spine and joints. Tumor necrosis factor inhibitors (TNFi), like adalimumab, are used to treat severe cases, but up to 25% of patients stop due to reduced effectiveness, often from anti-drug antibodies (ADA) forming [1]. Methotrexate (MTX), while ineffective alone in axial SpA, has shown potential in reducing the formation of ADA to TNFi [2, 3].

The objective of the study is to develop a mathematical model that describes the impact of MTX in reducing the immunogenicity of adalimumab in SpA. Based on mathematical models already established in the literature, an Ordinary Differential Equations (ODEs) model was formulated to describe the dynamics of the therapeutic compounds in the study (adalimumab and MTX, if applicable), the immune cells (T cells and B cells), and the relevant cytokines for the disease.

The data used to calibrate the model are sourced from a patient study [4], which involved 110 patients, from whom adalimumab concentration, lymphocyte counts, and antibody titers have been collected along five visits during the course of treatment.

Acknowledgements: This work is based upon work from COST Action ENOTTA CA21147, supported by COST (European Cooperation in Science and Technology).

References

- [1] A. V. Heinonen, K. J. Aaltonen, J. T. Joensuu, J. P. Lähteenmäki, M. I. Pertovaara, M. K. Romu, H. E. Hirvonen, A. K. Similä, M. L. Blom, D. C. Nordström, Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study, *The Journal of Rheumatology*, 42:2339–2346, 2015.
- [2] G. M. Bartelds, C. L. M. Kriekkaert, M. T. Nurmohamed, P. A. van Schouwenburg, W. F. Lems, J. W. R. Twisk, B. A. C. Dijkmans, L. Aarden, G. Jan Wolbink, Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up, *JAMA*, 305:1460–1468, 2011.
- [3] C. L. Kriekkaert, M. T. Nurmohamed, G. Jan Wolbink, Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner, *Annals of the Rheumatic Diseases*, 71:1914–1915, 2012.
- [4] E. Ducourau, T. Rispens, M. Samain, E. Dernis, F. Le Guilchard, L. Andras, A. Perdriger, E. Lespessailles, A. Martin, G. Cormier, T. Armingeat, V. Devauchelle-Pensec, E. Gervais, B. Le Goff, A. de Vries, E. Piver, G. Paintaud, C. Desvignes, D. Ternant, H. Watier, P. Goupille, D. Mulleman, Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial, *RMD Open*, 6:e001047, 2020.